The document outlines a comprehensive overview of the digital mental health (DMH) landscape, emphasizing its potential to enhance mental health care through technology-driven solutions such as telepsych, biosensors, and virtual reality. It identifies barriers to DMH adoption, including stigma and privacy concerns, while exploring applications across prevention, diagnosis, and treatment. Additionally, it discusses the role of pharmaceutical companies in integrating digital solutions with traditional mental health practices, highlighting both opportunities and challenges.

1. +
The Digital Mental Health Territory: A Pharma Overview
Craig A. DeLarge, Curator/Researcher, The Digital Mental Health Project
November 3, 2018
1
Copyright, 2018, WiseWorking, LLC

2. +
The Digital Mental Health Project?
■ Research & Strategy to
Accelerate the Responsible
Adoption of Digital in the
Mental Health Space.
■ A project portfolio to
educate, connect & curate
the work & experience of, the
global digital mental health
community of researchers,
entrepreneurs, treators and
users
2
Copyright, 2018, WiseWorking, LLC
Digital Stress Mgmt Survey
dMHp Blog DMH dbase
DMH Literacy Events

3. +
Copyright, 2018, WiseWorking, LLC
Applications Across the Care Continuum
3
Categories/
Care Continuum
Prevention Diagnosis Treatment Recovery
PsychoEducation x x x x
Care & Wellness
Platforms
x x x x
TelePsych x x x
BioSensors x x x x
Mixed Reality
(Virtual, Augm.)
x x x
Data Algorithms x x x x
Some Caveats:
● Mobile apps, games, neurostimulation not called out as they have significant
presence across all categories
● Care & Wellness Platforms subcategories include eMHR, eCBT, tele-psych,
meditation apps, etc.,

4. ++Significant Gap Fill Opportunities are
Emerging with Rise of DMH!
Gaps PsychEd T-Psych BioSensor C&W Platf. VR Data
Geo/Time Access x x x x x x
Financial Access x x x x
Early Detection x x x x x
Addressing Stigma x x x x
Education x x x
Diagnostic Accuracy x x x x x
Rx Effective./Efficiency x x x x
Tx Personalization x x x
Adhere & Follow-up x x x x
Tx Monitoring x x x
Suicide x x x x
Copyright, 2018, WiseWorking, LLC
4

5. + 5
Barriers to DMH Adoption
■ Stigma
■ Privacy & Security
■ Understanding of Clinical Efficacy
■ Affordability & Reimbursement

6. +
DMH Applications &
Categories
Copyright, 2018, WiseWorking, LLC
6

7. ++PsychoEducation: Providing Ubiquitous
Knowledge & Support
■ Manifests as websites, social
media, mobile apps, online
video & podcasts & virtual
reality & games
■ Value is expanding mental
health education reach and
access for treators, consumers,
carers, etc., anonymity for
stigma-concerned
■ Risk/barrier is accuracy,
overwhelming choices &
sources
Copyright, 2018, WiseWorking, LLC
7

8. ++Care & Wellness Platforms:
Improving “Line of (In)Sight”
■ Manifests in solutions providing
multi-function eXBT, records, (yes
eMR too!), monitoring, coordination,
decision support, etc. Take us
beyond point solutions.
■ Value is improved wellness/care &
treatment “line of sight” across care
continuum, silos & time; improved
decision support, coordination &
outcomes.
■ Risk/barrier is usability,
security/privacy, interoperability,
social/bureaucratic inertia &
reimbursement
Copyright, 2018, WiseWorking, LLC
8

9. ++TelePsych: Bridging Space & Time
(often also in C&W Platform subcategory)
■ Manifests as apps & sites giving
players (treator, consumer, carer)
access to one another via video,
phone, chat, etc., VR, & digital
therapeutics
■ Value is address of engagement
supply/demand discrepancies,
expanded access to proven
therapies & treator practice opps.
■ Risk/barrier is privacy/security,
social inertia, training, licensure
jurisdiction, reimbursement
Copyright, 2018, WiseWorking, LLC
9

10. ++BioSensors: DMH’s Eyes & Ears
■ Manifests as wearables,
digital therapeutics, sensor-
leveraging mobile apps
■ Value is in objective biometric
assessment & monitoring;
decision support expanding
ecosystem capacity to prevent
& treat
■ Risk/barrier is
security/privacy, ongoing
efficacy proof & social inertia
Copyright, 2018, WiseWorking, LLC
10

11. ++Virtual, Augmented & Mixed Reality: The
“Other Real” that Heals
■ Manifests in solutions providing
alternate reality simulations
delivering exposure, CBT,
embodiment (pain) & eye-tracking
therapies
■ Value is relatively low-cost, high-
access, controlled “trauma re-
exposure”, rich simulation &
biological monitoring
■ Risk/barrier is usability, tech
limits, social inertia,
reimbursement and ongoing
efficacy proof
Copyright, 2018, WiseWorking, LLC
11

12. ++Data & Algorithms:
DMH’s Brain, Mind & Mouth
■ Manifests as rules-based
decision support component in a
variety of solutions as well as firms
working to establish objective MH
biomarkers, outcomes models
■ Value is objective biometric
diagnosis & monitoring;
decision support expanding
ecosystem capacity to prevent &
treat unwellness
■ Risk/barrier is security/privacy,
validation & interoperability
Copyright, 2018, WiseWorking, LLC
12

13. +
DMH Pharma Overview
13

14. +
MentalPharma, pharma companies that
continue to focus on MH
Copyright, 2018, WiseWorking, LLC
14

15. +
DMH Engagement:
Copyright, 2018, WiseWorking, LLC
15
Collaboration to deliver caregiver resilience
support for caregivers of people with
schizophrenia. Also doing with Genentech
Collaboration for development of Japan-
specific ADHD solutions, tied to CSR stigma
program, HealthyMinds. Indigenization play.
J&J solutions suite with mobile
component, and part of multi-disease
platform offered to disease specific
customers.
Collaboration to develop ISTEP
(Integrated Smart Trial & Engagement
Platform), for clinical trials application

16. +
DMH Engagement:
Copyright, 2018, WiseWorking, LLC
16
Collaboration to deliver MDD app. Related to a
current drug commercial partnership and
shows how companies are bridging
traditional configurations to emergent.
Collaboration to deliver genomic MDD
assessment. Example of intersectoral
collaboration: pharma, digital health &
foundation.

17. +
DMH Engagement:
Copyright, 2018, WiseWorking, LLC
17
Collaboration to develop digital biomarkers
related to heart rate, motion and sleep
Collaboration to develop 1st FDA DTx
approval of pill + sensor + app offering
under single label
Collaboration with IBM to develop care
management platform for high-utilization
payor member management

18. +
DMH Engagement:
Copyright, 2018, WiseWorking, LLC
18
Collaboration to deliver and apply digital
biomarkers via digital phenotyping
Collaboration with Cognition Kit to integrate
Apple Watch sensors into MDD
assessment

19. +
DMH Engagement: Misc. Mentions
19
Collaboration to deliver meditation
instruction to company employees for
wellness
Collaboration to develop drug + app digital
therapeutic for schizophrenia
Collaboration to develop drug + app digital
therapeutic for depression

20. +
DMH Engagement: Misc. Mentions
Copyright, 2018, WiseWorking, LLC
20
Collaboration to use wearable to improve
seizure detection in drug clinical trial
Collaboration to improve ADHD clinical trial
performance using games

21. +
MentaPharma’s Application Trends
Copyright, 2018, WiseWorking, LLC
21
MentalPharm Janssen Otsuka L’beck Sunov. G’tech Sanofi Novartis
/Sandoz
Takeda/
Shire
Pill Augment X X X
Trial Improve X X X
Stigma X
Caregiver X X
3-way Partner X X
Strat. Extend. X X X
Care Platform X
Indigenize X

22. ++
MentaPharma’s Opps & Challenges
Opportunities:
■ Needs new business
futures
■ Has development, trial,
regulatory, commercial &
scale expertise
■ Deep, though hesitant,
pockets
■ Rigorous, and thus good
mentor & partner
Challenges:
■ Can be overly proprietary
■ Bureaucratic navigation &
threat
■ Rigorous, and thus slow
partner
■ Can be easily distracted &
lacking sense of urgency
22
Copyright, 2018, WiseWorking, LLC

23. +
Pharma Approach Considerations
§ Pharma’s Pet Peeves with DTx:
• more interested in short-term selling than in longer
term partnering
• point solutions versus holistic platforms
• viewing pharma as sales & distribution channel
§ When proposal failure occurs, often because of lack of:
• societal need,
• value-based & behavioral change case
• integration with Pharma BU
• integration with established care pathways
§ Pharma loves the value in DTx data and its insights
Copyright, 2018, WiseWorking, LLC
23

24. + 24
Craig A. DeLarge
Phone: +1-267-367-9867
Email: craig@wiseworking.com
Twitter: @DMentalHProject
Blog: https://medium.com/@dMHp
Digital Mental Health Project
Contact Information:
Copyright, 2018, WiseWorking, LLC

25. +
Copyright, 2018, WiseWorking, LLC
• Founder, The Digital Mental Health
Project + Former NAMI Board Member;
• Digital Health Strategist, Pharma
Marketer @ Takeda, IMS, J&J, GSK, NNI,
MSD
• Advisor: MedStartr, HackMentalHealth,
Galen Growth Asia, Henry Health, etc.
• Certified (Change) Leadership Coach
• Marketing, Strategy & Communications
Professor
• Author, The WiseWorking Handbook
• BS, Marketing, TJ University (US);
MBA, Design Mgmt., Univ. of Westminster
(UK);
MPH candidate, King’s College London
(UK)
Who Is Craig A. DeLarge?
25